Document Actions
Haematology Speakers 2009
Dr Drew Provan
Drew Provan is a general haematologist with a specific interest in immunohaematology. He is currently Senior Lecturer in Haematology at Bart’s & The London School of Medicine and Dentistry.
He studied molecular genetics at Leicester University before studying medicine. After junior medical posts in Scotland, Nottingham and Yorkshire, in 1993 he went to the Dana-Farber Cancer Institute in Boston, on an American travelling fellowship awarded by the Medical Research Council. He took up the post of consultant haematologist in Southampton in 1995, and moved to Barts & The London in 2000. He enjoys writing and editing and has been involved in the production of a number of books, including MRCP and MRCPath examination books, in addition to Molecular Haematology (Blackwell Science), Oxford Handbook of Clinical Haematology and Oxford Handbook of Clinical & Laboratory Investigation, and the ABC of Clinical Haematology (BMJ books).
Professor Tony Green
Tony Green is Head of the University of Cambridge Department of Haematology and Chairman of Addenbrooke's NHS Trust Department of Haematology. He trained in medicine at the University of Cambridge and University College Hospital London completing his haematology training at the Royal Free Hospital and the University Hospital of Wales, Cardiff. His scientific training in molecular biology and haematopoiesis was gained at the Imperial Cancer Research Fund, London and the Walter and Eliza Hall Institute, Melbourne, the latter as a Hamilton-Fairley Travelling Fellow. He moved to Cambridge in 1991 as a Welcome Trust Senior Fellow and was elected to the Chair of Haemato-Oncology there in 1999. His research interests focus on two aspects of haematopoietic stem cell biology: the molecular pathogenesis of myeloid malignancies and the transcriptional regulation of haematopoietic stem. Clinical research activities are mainly in the area of the myeloproliferative disorders.
Dr Charles Singer
Charles Singer has been a consultant haematologist at the Royal United Hospital Bath since 1988, having trained in general medicine and haematology at Glasgow Royal Infirmary and researched into bone marrow purging at University College London, where he developed his interest in multiple myeloma. He was chief investigator in two multicentre myeloma trials conducted in southwest England. Dr Singer was a founder member and first treasurer of the UK Myeloma Forum, which was established to improve collaboration in the treatment of this disease. He was involved in the development of the first two sets of UK Myeloma Forum/British Committee for Standards in Haematology guidelines for the management of myeloma and the development of the Myeloma IX trial. Dr Singer was treasurer for the British Society for Haematology, chairman of the haematology examiners for the Royal College of Pathologists and has recently taken up the position of treasurer for the Royal College of Pathologists.
Dr Robert Marcus
Robert Marcus qualified in medicine and pursued postgraduate studies in haematology at University College Hospital in London, subsequently becoming a research fellow at the MRC leukaemia unit at the Hammersmith Hospital, London. Dr Marcus completed his training in haematology at the Royal Free Hospital in London. He was appointed consultant haematologist at Addenbrooke’s Hospital in Cambridge in 1987 and participated in the first clinical studies in monoclonal antibody therapy for lymphoma with the CAMPATH series of antibodies. Dr Marcus later developed an interest in the development of novel treatments for lymphoma and has been chief investigator in a large number of phase 2 and 3 studies of chemotherapy and immunotherapy in lymphoma. He established stem cell transplantation in Cambridge and was, until recently, lead cancer clinician for Addenbrooke’s Hospital. Dr Marcus has published many papers and reviews on lymphoma and related topics in peer-reviewed journals and is the senior editor and contributor to the textbook, Lymphoma – pathology, diagnosis and treatment, published by Cambridge University Press in 2007. He is chairman of the NCRI low-grade lymphoma subgroup and has been consultant haematologist at King’s College Hospital, London, UK since February 2008.
Professor Ghulam Mufti
Professor Ghulam Mufti qualified in Medicine at the University of Kashmir in 1973. He came to the UK in 1975, and commenced his training in haematology at Radcliffe Infirmary, Oxford, and Hammersmith Hospital Royal Postgraduate Medical School. Because of his interest in pre-leukaemic states, in 1981 the Leukaemia Research Fund awarded him a grant for a fellowship in Bournemouth, Southampton & Royal Posgratduate Medical School. He was appointed as senior lecturer in haematological medicine and consultant haematologist in May 1985.
He has extensive clinical and research expertise in myelodysplastic syndrome (MDS), leukaemias, and lymphomas. The Unit at King’s is a leading centre for Bone Marrow Transplantation in MDS and he heads the research groups at King’s working on molecular genetics of MDS, genomic instability, chimerism, cell cycle and immunotherapy of myeloid malignancies, in particular MDS.
He has published numerous papers and chapters in scientific journals and textbooks on leukaemias. He devised the prognostic score (Bournemouth score for MDS) that initiated the search for other scores and contributed to the IPSS scoring system. He was a member of the working group that produced national and international guidelines on the treatment and prognosis of MDS. He is a member of the European Bone Marrow Transplantation Group and a founding member of the Board of the International Myelodysplastic Foundation of which his Department at King’s College Hospital is a recognised Centre of Excellence.
Dr Mark Layton
Dr Mark Layton is consultant haematologist and honorary reader in the Department of Haematology, Imperial College London. He was appointed in 2000 prior to which he was senior lecturer and consultant paediatric haematologist at King's College Hospital, London from 1990. His clinical and research interests are focused on inherited red cell disorders particularly haemoglobinopathies for which he leads a clinical service at Hammersmith and St Mary's Hospitals.
Dr Trevor Baglin
Trevor Baglin qualified in medicine from the University of Manchester with distinction in internal medicine in 1981. He then trained in internal medicine at Manchester and Newcastle-Upon-Tyne and in haematology at Birmingham and Cambridge. In 1989 he was awarded a PhD by the University of Birmingham for his thesis on platelet activation. Since 1990 Dr Baglin has been a consultant haematologist at Addenbrooke’s Hospital in Cambridge. He is the President-Elect of the British Society for Haemostasis and Thrombosis.
His main clinical and research interests are in haemostasis and thrombosis and he has developed a multidisciplinary team for the prevention and treatment of bleeding and thrombotic disorders, promoting out of hospital care and self management. Dr Baglin’s main research interests are in the regulation of thrombin generation and the use of laboratory tests as a measure of thrombosis risk. He has published more than 200 original clinical and scientific articles in peer-reviewed journals and for the past 6 years has been chairman of the haemostasis and thrombosis task force for the British Society for Haematology. He is an elected member of the scientific and standardisation subcommittee for the International Society for Haemostasis and Thrombosis (ISTH) and chairman of the subcommittee for control of anticoagulation for the ISTH.
He has held several appointments as an adviser on healthcare standards, including chairman of the regional haematology professional development group, chairman of the UK National External Quality Assessment Scheme (Coagulation) Steering Committee, regional adviser to the Royal College of Pathologists. He was also director of medical education at Addenbrooke’s Hospital from 1997 to 2000 and lead clinician for clinical governance at Addenbrooke’s Hospital from 2001 to 2008.
Dr Jim Murray
Dr Murray trained at Edinburgh and Sheffield before moving to Birmingham. He is a general haematologist with an interest in morphology. He is secretary of the BCSH General Haematology task Force and Chair of the Panel of Examiners for Haematology.
